Michael A. Lockshin, MD Director, Barbara Volcker Center for Women and Rheumatic Disease; Co-director, Mary Kirkland Center for Lupus Research at HSS
Jane E. Salmon, MD Collette Kean Research Chair; Co-director, Mary Kirkland Center for Lupus Research at HSS
LAC Strongest Indicator of Advese Outcome in aPL-Associated Pregnancies PROMISSE Study Overturns Common Belief The presence of lupus anticoagulant (LAC) is the primary predictor of adverse pregnancy outcome after 12 weeks’ gestation in aPL-associated pregnancies. Other antibodies in the same family, thought to cause pregnancy complications, do not put women at increased risk. Anticardiolipin antibody and anti-β2 GPI – if LAC is not also present – do not predict adverse pregnancy outcome. These findings are from the first clinical research publication of PROMISSE – the largest ever study of pregnancy outcomes in women with lupus and/or aPL.
Published in Arthritis & Rheumatism, July 2012. Full Details on study and PROMISSE on HSS.edu
Learn more about the HSS Rheumatology Research Studies presented at the 2012 ACR Meeting.